Furthermore, deficiency in CD8+ Treg function is not limited to the blood, as evidenced by the significantly reduced CD8+ T-cell cloning frequency in the CSF during MS relapse as compared to remission, suggesting loss of CD8+ Tregs in the CSF during relapse (142). This evidence concerns the gene CD8A and myeloid sarcoma.